Literature DB >> 7693284

The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.

S Guard1, S J Boyle, K W Tang, K J Watling, A T McKnight, G N Woodruff.   

Abstract

1. We investigated the effects of the non-peptide NK1 receptor antagonist, CP-96,345, its inactive enantiomer CP-96,344, and the racemic mixture (+/-)-CP-96,345, on the binding of [3H]-nimodipine and [3H]-diltiazem to L-type calcium channels in rat cerebral cortex membranes. In isolated peripheral tissues containing tachykinin receptors, the effects of (+/-)-CP-96,345 have been compared with those of diltiazem. 2. In guinea-pig trachea, (+/-)-CP-96,345 produced antagonism of responses to the selective NK1 agonists [Sar9, Met(O2)11]SP and substance P-methyl ester that was apparently competitive in nature (pKB 7.0-7.5), while in guinea-pig ileum the antagonism was not surmountable. 3. The reduction of maximum responses by (+/-)-CP-96,345 in the guinea-pig ileum was not selective; it was obtained with muscarinic agonists and other agents, and was also observed in the portal vein of the rat where NK1 receptors are not present. 4. The tissue-specific reduction of maximum responses by (+/-)-CP-96,345 in ileum was reproduced by diltiazem. 5. (+/-)-CP-96,345 produced a concentration-dependent enhancement of [3H]-nimodipine binding to rat cerebral cortex membranes with a maximal stimulation of 186 +/- 29% above control (EC50 83.2 nM). Scatchard analysis revealed that (+/-)-CP-96,345 increased the affinity of [3H]-nimodipine for its binding sites without affecting Bmax (control: KD = 0.32 nM; with 100 nM (+/-)-CP-96,345: KD = 0.074 nM). 6. CP-96,345, CP-96,344, and the racemate all inhibited [3H]-diltiazem binding in rat cerebral cortex membranes with Ki values of 22.5 nM, 34.5 nM and 29.9 nM respectively; a similar value was obtained for diltiazem itself (33.6 nM). In comparison, CP-96,345 and ( +/- )-CP-96,345 inhibited the binding of[125I]-Bolton-Hunter-conjugated substance P in this tissue with Ki values of 59.6 nM and 82.0 nM respectively, while CP-96,344 had no measurable affinity (IC50> 10 microM).7. Substance P and a range of ligands selective for NK1, NK2, or NK3 receptors had no significant effect at 10 microM on either [3H]-diltiazem or [3H]-nimodipine binding.8. The results indicate that in addition to possessing affinity for the NK1 receptor, the non-peptide antagonist, CP-96,345, displays high affinity for [3H]-diltiazem binding sites on L-type calcium channels.The functional effect that may be observed in integrated models will be a consequence of either property, or be a composite effect of NK1 receptor antagonism and L-channel blockade.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693284      PMCID: PMC2176003          DOI: 10.1111/j.1476-5381.1993.tb13821.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

Review 1.  Tachykinins.

Authors:  J E Maggio
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

2.  Temperature-dependent modulation of [3H]nitrendipine binding by the calcium channel antagonists verapamil and diltiazem in rat brain synaptosomes.

Authors:  R G Boles; H I Yamamura; H Schoemaker; W R Roeske
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

Review 3.  Substance P.

Authors:  B Pernow
Journal:  Pharmacol Rev       Date:  1983-06       Impact factor: 25.468

4.  Specific binding of [3H]nitrendipine to membranes from coronary arteries and heart in relation to pharmacological effects. Paradoxical stimulation by diltiazem.

Authors:  A DePover; M A Matlib; S W Lee; G P Dubé; I L Grupp; G Grupp; A Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1982-09-16       Impact factor: 3.575

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex.

Authors:  H Schoemaker; S Z Langer
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

7.  A potent nonpeptide antagonist of the substance P (NK1) receptor.

Authors:  R M Snider; J W Constantine; J A Lowe; K P Longo; W S Lebel; H A Woody; S E Drozda; M C Desai; F J Vinick; R W Spencer
Journal:  Science       Date:  1991-01-25       Impact factor: 47.728

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.

Authors:  G T Bolger; P Gengo; R Klockowski; E Luchowski; H Siegel; R A Janis; A M Triggle; D J Triggle
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

10.  Multiple tachykinin binding sites in peripheral tissues and in brain.

Authors:  C M Lee; N J Campbell; B J Williams; L L Iversen
Journal:  Eur J Pharmacol       Date:  1986-11-04       Impact factor: 4.432

View more
  14 in total

1.  Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist.

Authors:  Z Y Wang; S R Tung; G R Strichartz; R Håkanson
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

2.  Non-specific actions of the non-peptide tachykinin receptor antagonists, CP-96,345, RP 67580 and SR 48968, on neurotransmission.

Authors:  Z Y Wang; S R Tung; G R Strichartz; R Håkanson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

3.  The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

Authors:  D T Beattie; I J Beresford; H E Connor; F H Marshall; A B Hawcock; R M Hagan; J Bowers; P J Birch; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.

Authors:  E Cellier; L Barbot; S Iyengar; R Couture
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  An isobolographic analysis of the effects of N-methyl-D-aspartate and NK1 tachykinin receptor antagonists on inflammatory hyperalgesia in the rat.

Authors:  K Ren; M J Iadarola; R Dubner
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Acid-induced mesenteric hyperemia in rats: role of CGRP, substance P, prostaglandin, adenosine, and histamine.

Authors:  Felix W Leung; Fumihiro Iwata; Kyoji Seno; Joseph W C Leung
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

8.  Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.

Authors:  W S Lee; S M Moussaoui; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

9.  Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.

Authors:  P Picard; D Regoli; R Couture
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

10.  Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord.

Authors:  M Malcangio; N G Bowery
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.